# Long-Term Open-Label Extension Study of Oral Levosimendan

Study · id `cardio:ct-nct07436689` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07436689](<https://clinicaltrials.gov/study/NCT07436689>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07436689

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 800 participants.

## Technical summary

Registry record NCT07436689. Allocation not applicable; no masking; primary purpose treatment. Start 2026-03-13 (actual); primary completion 2029-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 800 participants (planned count; ClinicalTrials.gov record NCT07436689, source copy `cardio:ctgov-nct07436689-2026-10-20`, retrieved 2026-10-26)
- Started: 2026-03-13 (actual) (ClinicalTrials.gov record NCT07436689, source copy `cardio:ctgov-nct07436689-2026-10-20`, retrieved 2026-10-26)
- Primary completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT07436689, source copy `cardio:ctgov-nct07436689-2026-10-20`, retrieved 2026-10-26)
- Completion: 2029-03 (anticipated) (ClinicalTrials.gov record NCT07436689, source copy `cardio:ctgov-nct07436689-2026-10-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07436689, source copy `cardio:ctgov-nct07436689-2026-10-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07436689-2026-10-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-Term Open-Label Extension Study of Oral Levosimendan
- Condition: Pulmonary Hypertension Associated With HFpEF
- Intervention (Drug): TNX-103
- Lead sponsor: Tenax Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Tenax Therapeutics, Inc. (`cardio:org-tenax-therapeutics-inc`)

## Provenance

Content hash: f36d37cb5bd4290b0f540457c1d622f89ae70de47d7e51a6633a871e80677b5c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
